CHAARTED2: Improving Outcomes in Patients With mCRPC

Christos Kyriakopoulos, MD, of University of Wisconsin, and Vadim Koshkin, MD, of University of California, San Francisco, break down the CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group, an evaluation of cabazitaxel with abiraterone versus abiraterone alone for CRPC following docetaxel.

Together, they highlight the key data takeaways and how clinicians should interpret the benefits of combining these therapies, especially when considering treatment-related adverse events.